Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) will report full-year 2025 financial results and host a corporate update conference call and webcast on Thursday, March 19, 2026 at 8:30 AM ET.

Investors can access the live webcast and later archived replay via the company’s Events and Presentations page at ir.tayshagtx.com for the company update and Q&A.

News Market Reaction – TSHA

+2.10%

1 alert

+2.10% News Effect

On the day this news was published, TSHA gained 2.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash balance: $297.3M R&D expense: $25.7M Net loss: $32.7M +5 more

8 metrics

Cash balance $297.3M Q3 2025 cash, runway into 2028

R&D expense $25.7M Q3 2025 research and development spend

Net loss $32.7M Q3 2025 quarterly net loss

REVEAL dose 1x10^15 vg Single intrathecal dose in pivotal Rett trial

REVEAL sample size 15 females Planned enrollment, ages 6 to <22 years

Interim analysis window 6 months REVEAL interim analysis that may support BLA

Breakthrough Therapy Designation granted TSHA-102 for Rett syndrome, reported 2025-11-04

RTW ownership 8.3% 23,407,133 shares beneficially owned via SCHEDULE 13G/A

Market Reality Check

Price: $4.53 Vol: Volume 2,218,299 is at 0....

normal vol

$4.53 Last Close

Volume Volume 2,218,299 is at 0.94x the 20-day average (2,362,119). normal

Technical Shares at $4.52, trading above the 200-day MA of $3.89, about 25% below the 52-week high of $6.02.

Peers on Argus

Momentum scanner shows mixed sector action: OCS and SANA up (~2.5–2.9%), while I...

2 Up 2 Down

Momentum scanner shows mixed sector action: OCS and SANA up (~2.5–2.9%), while IOVA and UPB are down (~1.9–2.0%). This points to broader biotech cross-currents rather than a TSHA-specific move on the scheduling of its earnings call.

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Inducement equity awards	Neutral	+1.8%	RSUs and options granted to two new employees under inducement plan.
Feb 06	Inducement RSU grants	Neutral	+4.5%	Inducement RSUs totaling 349,000 shares granted to three new employees.
Jan 06	Rett pivotal progress	Positive	+7.6%	First REVEAL pivotal patient dosed; FDA alignment on BLA-enabling dataset.
Dec 05	Inducement stock options	Neutral	+7.9%	Options for 212,000 shares with 10-year term and four-year vesting granted.
Nov 04	Q3 2025 earnings	Positive	-4.3%	Reported Q3 2025 results, TSHA-102 Breakthrough Therapy, and $297.3M cash runway.

Pattern Detected

Clinical and corporate updates have often seen positive price reactions, while the last detailed earnings/corporate update drew a negative move, indicating occasional divergence on fundamentally positive news.

Recent Company History

Over the past six months, TSHA has combined steady corporate activity with advancing its Rett syndrome program. Multiple inducement grants under Nasdaq Listing Rule 5635(c)(4) in Nov 2025, Dec 2025, Feb 2026, and Mar 2026 supported hiring and retention, generally with modestly positive price reactions. A pivotal update on TSHA-102 in Jan 6, 2026 and earlier Q3 2025-11-04 earnings highlighted FDA Breakthrough Therapy designation, an accelerated BLA path, and cash of $297.3M. Today’s notice simply schedules the next full-year 2025 results and update.

Market Pulse Summary

This announcement simply sets the timetable for TSHA’s full-year 2025 results and corporate update o...

Analysis

This announcement simply sets the timetable for TSHA’s full-year 2025 results and corporate update on March 19, without offering new financial or clinical metrics. Context from recent history matters: Q3 2025 featured $297.3M in cash with runway into 2028 and FDA Breakthrough Therapy designation for TSHA-102, while subsequent updates highlighted progress in the Rett pivotal program. Investors may focus on cash runway, R&D spending, and pivotal trial timelines when those full-year figures and commentary are released.

Key Terms

adeno-associated virus, aav, central nervous system, cns, +3 more

7 terms

adeno-associated virus medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"

Adeno-associated virus (AAV) is a naturally occurring, small virus that researchers use as a safe carrier to deliver corrective genes into human cells, much like a specialized delivery van transporting instructions to a malfunctioning machine. It matters to investors because AAV-based therapies drive large development costs, unique manufacturing and regulatory risks, and the potential for high-value, one-time treatments that can significantly affect a biotech company’s future revenue and valuation.

aav medical

"advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic"

AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.

central nervous system medical

"diseases of the central nervous system (CNS), today announced that it will report"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"diseases of the central nervous system (CNS), today announced that it will report"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

breakthrough therapy designation regulatory

"TSHA-102 received FDA Breakthrough Therapy designation for Rett syndrome and the"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

intrathecal medical

"open-label study of a single intrathecal dose of 1x10^15 vg in 15 females"

Intrathecal describes a method of delivering a drug or therapy directly into the fluid-filled space around the spinal cord and brain so the medicine reaches the central nervous system more directly. For investors, intrathecal delivery matters because it often signals higher development complexity, specialized manufacturing and administration, and greater regulatory and safety scrutiny—factors that can affect costs, timelines and market adoption like choosing a specialist tool instead of a general one.

rule 144 financial

"insider plans small stock sale under Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

AI-generated analysis. Not financial advice.

DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time.

Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

When will Taysha (TSHA) release full-year 2025 financial results and hold the webcast?

Taysha will release full-year 2025 results and host a webcast on March 19, 2026 at 8:30 AM ET. According to the company, the live webcast will be available on its Events and Presentations page and an archived replay will be posted afterward.

How can investors access Taysha Gene Therapies (TSHA) live conference call and replay?

Investors can access the live conference call and replay via the company’s Events and Presentations page at ir.tayshagtx.com. According to the company, the webcast will stream live on March 19, 2026 with an archived replay available on the website afterward.

What time is Taysha’s (TSHA) corporate update call on March 19, 2026?

The corporate update call is scheduled for 8:30 AM Eastern Time on March 19, 2026. According to the company, the session will include a corporate update and Q&A and will be webcast live on the investor site with a replay posted later.

Will Taysha (TSHA) provide an archived replay of the March 19, 2026 webcast?

Yes, an archived replay will be available on the company website after the live event. According to the company, the webcast will be posted on its Events and Presentations page so investors can review the full corporate update and Q&A afterward.

What topics will Taysha (TSHA) likely cover in the March 19, 2026 corporate update webcast?

The webcast will cover the company’s full-year 2025 financial results and a corporate update on clinical progress and strategy. According to the company, the event will include management remarks and a Q&A session accessible via the live webcast and archived replay.